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ABSTRACT A rare set of hematopoietic stem cells (HSC)
must undergo a massive expansion to produce mature blood
cells. The phenotypic isolation of HSC from mice offers the
opportunity to determine directly their proliferation kinetics.
We analyzed the proliferation and cell cycle kinetics of long-
term self-renewing HSC (LT-HSC) in normal adult mice. At
any one time, '5% of LT-HSC were in SyG2yM phases of the
cell cycle and another 20% were in G1 phase. BrdUrd incor-
poration was used to determine the rate at which different
cohorts of HSC entered the cell cycle over time. About 50% of
LT-HSC incorporated BrdUrd by 6 days and >90% incorpo-
rated BrdUrd by 30 days. By 6 months, 99% of LT-HSC had
incorporated BrdUrd. We calculated that approximately 8% of
LT-HSC asynchronously entered the cell cycle per day. Nested
reverse transcription–PCR analysis revealed cyclin D2 expres-
sion in a high proportion of LT-HSC. Although '75% of
LT-HSC are quiescent in G0 at any one time, all HSC are
recruited into cycle regularly such that 99% of LT-HSC divide
on average every 57 days.
Hematopoiesis is a dynamic process resulting in the continuous
production of at least eight separate lineages of cells. The
hematopoietic tissues of an adult mouse must replace approx-
imately 2.4 3 108 red blood cells and 4 3 106 nonlymphoid
peripheral blood cells each day (1) and compensate for
hematological stresses such as blood loss, infection, and in-
gestion of cytotoxic chemicals. Such demands necessitate strict
control over hematopoietic progenitor proliferation. All cells
produced by the hematopoietic system are derived from he-
matopoietic stem cells (HSC) that reside mainly in the bone
marrow (BM). HSC are defined at the single-cell level by their
ability to self-renew and to give rise to all lineages of blood cells
(2). The multipotent progenitor pool is heterogeneous and can
be divided into colonogenic long-term self-renewing HSC
(LT-HSC), transiently self-renewing HSC (short-term HSC),
and non-self-renewing multipotent progenitors (MPP) (3).
The clonal-succession hypothesis (4) proposed a model for
how LT-HSC coordinate cell cycle events to meet the demands
of hematopoiesis. The model postulated that there is a large
supply of HSC representing the only source of mature blood
cells for the lifetime of the animal, but that only one or a few
HSC clones give rise to mature blood cells at any time. Other
HSC were postulated to remain quiescent and not contribute
to hematopoiesis until the proliferative capacity of the active
LT-HSC clone is exhausted. The reconstitution patterns from
several experiments in which retrovirally marked hematopoi-
etic progenitors were used to reconstitute irradiated mice were
interpreted to support the clonal-succession model (5–7). The
contributions of individual clones of retrovirus-infected HSC
to hematopoiesis were followed by monitoring the different
retroviral integration sites in mature blood cells. In these
experiments, only one or a few LT-HSC clones appeared to
contribute to blood cell production at any one time (5–7).
Subsequent retroviral marking studies observed that many
clones contributed to hematopoiesis, with extensive clonal
f luctuation for a long post-transplant period, followed by
equilibration to oligoclonal reconstitution (8, 9); part of this
post-transplant fluctuation could reflect the fact that different
classes of HSC have different self-renewal potentials (3, 10).
Analogous experiments in a large animal model, the cat, also
revealed large clonal f luctuations post-transplant that have
been interpreted to support clonal succession (11); however,
some of the cats failed to engraft and had to be retransplanted.
It was later calculated that the bone marrow used to recon-
stitute these cats contained only 6–12 HSC per kg body mass
(12). This raises the question of whether enough HSC engraft
in transplantation models to test whether many HSC normally
contribute to hematopoiesis. Indeed, it has been argued that
reconstitution assays may not be an appropriate test of the
clonal succession hypothesis because they do not represent
steady-state hematopoiesis and because only limited numbers
of HSC typically engraft (9). Therefore, it may not be surpris-
ing that in reconstituted animals, only a few transplanted
clones contribute to hematopoiesis. To avoid reconstitution
effects, Harrison et al. (13) prepared embryonic chimeric mice
in which HSC were derived from embryonic stem (ES) cells of
two different genotypes. Because there was little variability in
the relative contributions of the two genotypes over time,
Harrison et al. concluded that many HSC simultaneously
contribute to hematopoiesis in mice.
Although experiments by Harrison and colleagues demon-
strated that many HSC contribute simultaneously to hemato-
poiesis, it remains possible that only certain subsets of HSC are
active during each period in the life history of an animal. To
investigate this possibility, the proliferation history of HSC has
been analyzed directly. The BrdUrd incorporation rates of
primitive hematopoietic progenitors have been analyzed by
exposing mice to subtoxic doses of BrdUrd to label the nuclei
of dividing cells. In an early and important study, Pietrzyk et
al. (14) analyzed the BrdUrd incorporation rates of day-14
colony-forming units spleen (CFU-S), a population that in-
cludes HSC as well as other MPP and myeloerythroid pro-
genitors. They demonstrated that '75% of progenitors capa-
ble of forming day-14 spleen colonies had incorporated Br-
dUrd over a 32-day period of normal hematopoiesis. Bradford
et al. (15) analyzed the proliferation kinetics of highly enriched
HSC defined by Hoechst (Ho) and Rhodamine 123 (Rho)
exclusion. They demonstrated that up to 89% of HoloRholo
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progenitors incorporated BrdUrd over a period of 12 weeks.
Thus, both the Pietrzyk et al. and Bradford et al. studies were
consistent with the idea that a majority of HSC divide regularly.
Despite these important advances, a more complete view of
LT-HSC cell cycle kinetics has not been presented. The
relative distribution between the G1 and G0 phases of the cell
cycle, as well as the average cell cycle times have not been
determined for HSC in vivo. Furthermore, it remains possible
that up to 10% of HSC may remain quiescent for very long
periods of time. If true, this could have fundamental implica-
tions for heterogeneity in and regulation of the HSC pool. In
this study, we determined the in vivo proliferative history and
cell cycle status of mouse HSC purified by fluorescence-
activated cell sorting. All HSC activity in C57BLyKa-Thy 1.1
mice is contained within c-kitbright, Thy 1.1lo, Sca-11, Lineage 2ylo
(KTSL2ylo) fraction of BM (3, 16–18). KTSL2ylo cells are
heterogeneous, containing all LT-HSC as well as short-term
HSC and MPP (3, 10). The LT-HSC subset can be isolated by
purifying the lineage-negative subset of these cells (KTSL2)
(3). We examined the proliferation history of the KTSL2 and
KTSL2ylo HSC populations by studying their in vivo BrdUrd
incorporation kinetics. Cells from either population (99%
total) incorporated BrdUrd over a period of 3–6 months,
demonstrating that all HSC cycle regularly. At any one time,
'25% of LT-HSC were either in G1 or SyG2yM phases of the
cell cycle. Consistent with this, a high proportion of LT-HSC
expressed cyclin D2 mRNA. We present a model describing
the LT-HSC cell cycle kinetics.
MATERIALS AND METHODS
Mouse Strains. C57BLyKa-Ly 5.1, Thy 1.1 and C57BLy
Ka-Ly 5.2, Thy 1.1 mice were bred and maintained in the
Stanford University School of Medicine animal care facility.
Mice were maintained on acidified water (pH 2.5) until
BrdUrd treatment. All mice were 6–12 weeks old at the
initiation of treatment.
BrdUrd Treatment of Mice. Aged-matched mice were al-
lowed to freely imbibe sterile deionized water containing
BrdUrd (1 mgyml; Sigma) for 3, 6, 10, 15, 20, 30, or 180 days.
Containers of BrdUrd water were wrapped in aluminum foil to
prevent light exposure and were changed every 3–6 days. For
the zero time point, mice were given an intraperitoneal (i.p.)
injection of BrdUrd in 0.9% saline (1 mg of BrdUrd per 6 g of
body weight). After 90 min, the mice were sacrificed for
isolation of HSC.
Control Experiments for BrdUrd Toxicity. To ensure there
was no alteration of hematopoiesis by BrdUrd, complete blood
counts were performed by using tail-vein blood from age-
matched mice that were fed BrdUrd for 6 days (n 5 5) and
from mice not fed BrdUrd (n 5 9). BM cells from the left leg
of mice exposed to BrdUrd for 10 days (n 5 6) and age-
matched controls (n 5 6) were counted by using trypan blue
exclusion. BM cells were also stained with antibodies against
myeloid [M1y70 (anti-Mac-1) and 8C5 (anti-Gr-1)] and lym-
phoid [KT31.1 (anti-CD3) and 6B2 (anti-B220)] markers and
analyzed by dual-laser f luorescence-activated cell sorting
(FACS, Vantage, Becton Dickinson). The Hoechst DNA
profiles of BM and HSC from BrdUrd-exposed mice were
compared with controls as described (3). To test whether
BrdUrd administration had an effect on HSC function, cells
from treated donors were examined by a limit dilution com-
petitive reconstitution assay as described (3).
Antibodies. The antibodies used in immunofluorescence
staining included: 19XE5 (anti-Thy 1.1), E13 (anti-Sca-1, Ly6
AyE), 2B8 (anti-c-kit), and the Lineage markers GK1.5 (anti-
CD4), 53–56.7 (anti-CD8), KT31.1 (anti-CD3), 53.73 (anti-
CD5), 6B2 (anti-B220), Ter 119 (anti-erythroid specific anti-
gen), 8C5 (anti-Gr-1), M1y70 (anti-Mac-1). Monoclonal an-
tibody BU-1 (Caltag, South San Francisco, CA) was used for
BrdUrd analysis.
HSC Isolation. All procedures were done in UV-free light
to prevent the degradation of BrdUrd in samples and the
photoactivation of BrdUrd in DNA. Marrow was flushed and
pooled from the femurs and tibias of groups of five aged-
matched mice that had been allowed to imbibe water contain-
ing BrdUrd for equal amounts of time. BM was stained for
HSC isolation as described (3). HSC were isolated with a
dual-laser FACS. BM preparations were sorted on the basis of
high expression of c-kit, low expression of Thy 1.1, positive
expression of Sca-1, and a negative-to-low level expression of
lineage markers (KTSL2ylo). This isolated the entire HSC
pool, including LT-HSC, short-term HSC, and MPP (3, 10).
Nearly pure populations of LT-HSC were isolated by sorting
cells with no detectable levels of lineage marker staining and
were thus Lineage-negative (KTSL2) (3, 10). To ensure purity,
all HSC populations were double sorted to 95% purity. HSC
were directly sorted onto a chambered glass microscope slide
pretreated with the histological adhesive Cell-Tak (Collabo-
rative Biomedical Products, Bedford, MA), according to man-
ufacturer’s instructions.
BrdUrd Staining. HSC sorted on to chambered slides were
spun down and fixed with 70% ethanol at minus 20°C for 30
minutes. DNA was denatured with 2 M HCL 1 0.8% Triton
X-100. Between each procedure, the slides were washed 3
times for 5 min in PBS. The acid was neutralized with 0.1 M
sodium borate. The slide was then incubated with staining
medium (PBS 1 0.1% Nonidet P-40 1 4% goat serum) for 1
hour. The HSC were stained with anti-BrdUrd mAb for 1 hour
at room temperature, washed, and stained with fluorescein
isothiocyanate-conjugated anti-mouse antibodies (Caltag,
South San Francisco, CA) for 1 hour at room temperature. All
antibodies were diluted in the staining medium described
above. Finally, cells were mounted in 1:1 glycerolyPBS con-
taining 1 mgyml Hoechst 33342 (Sigma).
Microscopic Analysis of BrdUrd Staining. BrdUrd-positive
HSC were counted by using a Nikon FXA fluorescent micro-
scope at 3400 magnification. Cell nuclei were first counted by
using the Hoechst filter, then the fluorescein isothiocyanatey
Texas Red filter was used to count the number of BrdUrd-
positive (green) HSC in the same field. Thymocytes or double-
sorted Thy1.1lo BM cells from mice not exposed to BrdUrd
were used as negative controls for each experiment. The
fluorescein isothiocyanate stain from the Thy 1.1 antibody was
not visible on cells after BrdUrd staining. For most time points,
HSC were obtained from at least three groups with five mice
per group, and 1,500 HSC were scored. For three time points
(day 0, day 20-KTSL2, and day 30 KTSL2ylo), HSC were
obtained from two groups of five mice, but in each case at least
500 cells were counted.
Cyclin D2 Reverse Transcription–PCR (RT-PCR). Single
KTSL2 LT-HSC were directly clone sorted into U-bottom
96-well plates filled with 19 ml of RT lysis buffer containing
cyclin D2-specific RT primer and salts as described (19) by
using nested cyclin D2-specific PCR primers. After 70 (35 3
2) amplification cycles, 10 ml of PCR products were electro-
phoresed through a 1.5% agarose gel, and the PCR products
were visualized in the ethidium bromide-stained gels. The
sequences of all RT and PCR primers can be obtained from
S.H.C. (e-mail: cheshier@leland.stanford.edu). The PCR
primers were selected to be specific only for cyclin D2 and gave
no PCR product when used in PCR reactions containing cyclin
D1 or D3 cDNAs or in reactions with mouse genomic DNA or
splenic T cells that do not express cyclin D2 (data not shown).
PCR with cyclin D2 primers always resulted in a single band of
the appropriate size (331 bp) that hybridized to an internal cyclin
D2-specific probe on Southern blot analysis (data not shown).
Pyronin Y (PY)yHoechst Staining. KTSL2 LT-HSC were
isolated as described above, double-sorted into a V-bottom
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96-well plate containing 100 ml of Hanks Balanced Salt
Sownen (GIBCO) 1 2% bovine calf serum, and stained for
Hoechst and PY as described (20). Samples were then placed
on ice for 15 min, and propidium iodide was added to a final
concentration of 0.5 mgyml for exclusion of dead cells. Fluo-
rescence-activated cell sorting analysis of these cells was
performed on a FACSTAR Plus (Becton Dickinson) equipped
with UV-laser.
RESULTS
BrdUrd Does Not Alter Normal Hematopoiesis or HSC
Function. HSC were labeled in vivo by allowing mice to drink
BrdUrd in their water. Some studies have demonstrated that
low levels of BrdUrd are not toxic to cells (14, 21), but others
have documented alterations of gene expression and cellular
toxicity because of the presence of this molecule (22, 23). To
ascertain whether the BrdUrd doses used in this study altered
normal hematopoiesis, we measured several BM and HSC
functional parameters in mice exposed to BrdUrd and com-
pared them to normal controls. We saw no differences in
peripheral blood counts (white blood cells, red blood cells,
neutrophils, band cells, and lymphocytes), or in the proportion
of lymphoid cells in the BM (Table 1). There was, however, a
slight increase in both Gr-1 and Mac-1-positive cells in the BM
of mice that received BrdUrd for 10 days (Table 1). Although
statistically significant, the increases were very small. If Br-
dUrd exposure altered HSC proliferation kinetics, changes in
the normal proportions of HSC in SyG2yM phases of the cell
cycle should have been apparent. However, the percentage of
BM and HSC (KTSL2 and KTSL2ylo) with .2n DNA was not
significantly altered even after a 10 day exposure to BrdUrd
(Table 2). KTSL2 HSC from mice fed BrdUrd for 10 days were
just as effective as normal KTSL2 HSC in the limit2dilution
long-term competitive reconstitution assay, with limit2
dilution dose of around 1 in 12 cells (Table 2). We conclude
that the doses of BrdUrd used in this study did not significantly
alter normal HSC biology.
In Vivo Proliferation Kinetics of HSC. To determine the
proliferative history of HSC, we isolated KTSL2ylo and KTSL2
HSC (Fig. 1) from the BM of mice that were fed BrdUrd.
Consistent with our observation that '11% of KTSL2ylo cells
were in SyG2yM phases of the cell cycle (ref. 30; Table 2), an
average of 13.2% of these cells labeled immediately after a
single pulse of BrdUrd. KTSL2ylo cells entered S phase at a
rapid rate, with an average of 78.4% BrdUrd-labeled cells by
day 6, 87.8% by day 10, and virtually all cells by day 30 (99.4%;
Fig. 2A). The fact that .99% of KTSL2ylo cells incorporate
BrdUrd over a 30-day period suggests that no subset of HSC
remains quiescent for more than 30 days. We wished to test
further whether there was a significant lag in BrdUrd incor-
poration in LT-HSC (KTSL2). Again consistent with the
steady-state level of '4–6% of these cells in SyG2yM (ref. 3;
Table 2), an average of 4.7% of these cells were labeled
immediately after BrdUrd administration; an average of 52.2%
were labeled by 6 days, and after 30 days, .90% were
Table 1. Control experiments for the effects of BrdUrd on peripheral blood and BM populations
1BrdU 2BrdU
Peripheral Blood Counts White blood cells 6.2 6 1.6 8.0 6 2.2
Platelet counts 1,488 6 531 1,404 6 374
Neutrophils 10.0 6 2.9 9.9 6 3.8
Lymphocytes 85.8 6 3.6 87.8 6 4.3
Reticulocytes 1.96 6 0.58 2.1 6 0.42
WBM cell populations Total cell # Leg Bone 3.64 6 0.43 3.86 6 0.51
Gr-1‡ 35.7 6 3.3 29.4 6 0.4
Mac-1‡ 38.9 6 2.75 34.9 6 1.5
B220 30.3 6 5.1 34.8 6 0.45
CD3 2.37 6 0.12 2.04 6 0.06
All data are given as mean 6 SD. Peripheral blood counts from the tail vein of mice exposed to BrdU
for 6 days (n 5 5) compared to aged matched controls not receiving BrdU (n 5 9). No statistical
differences (P . 0.05) were seen in any parameters using Student’s t test statistics. BM Cells from the
left leg bones of mice exposed to BrdUrd for 10 days (n 5 6) and age-matched controls (n 5 6) were
counted by using Trypan blue exclusion. BM cells were also stained with antibodies against myeloid and
lymphoid lineage markers and analyzed by using fluorescence-activated all sorting. No statistical
differences (P . 0.05) were seen in BM cell numbers or % B220 and CD3 in BM using Student’s t test
statistics.
‡The differences in % Gr-1- and Mac-1-positive BM were statistically significant (P 5 0.001 and P 5 0.01
respectively) using Student’s t test statistics.
Table 2. Control experiments for effects of BrdU on KTSL2ylo and KTSL2 HSC
BrdUrd
Hoechst DNA Staining
CLDCRSyG2yM WBM, % SyG2yM KTSL2ylo, % SyG2yM KTSL2, %
Present 11.1 6 2.6 10.9 6 3.7 6.2 6 2.6 9y17
Absent 12.85 6 2.0 11.2 6 2.6 5.7 6 2.2 6y10
All values are given as mean 6 SD. BM from mice exposed to BrdUrd for 10 days (n 5 5) and age-matched controls (n 5
5) was stained with Hoechst 33342 and then stained with antibodies against c-Kit, Thy 1.1, Sca-1, and Lineage markers as
described in Materials and Methods. DNA analysis was performed on dual-laser FACS Vantage equipped with UV laser. No
statistical differences (P . 0.05) were seen using Student’s t test. To test whether BrdU administration had an effect on HSC
function, cells from treated donors were examined by a clonal limit dilution competitive reconstitution assay (CLDCR). Twelve
KTSL2 HSC from C57BLyKa-Ly 5.1, Thy 1.1 mice exposed to BrdUrd for 10 days and 2 3 105 Ly 5.2 BM cells were injected
into lethally irradiated (4.75 Gy 3 2 5 9.5 Gy) Ly 5.2 congenic hosts (n 5 17). 12 KTSL2 HSC from non-Brd Urd-exposed
mice and 2 3 105 Ly 5.2 BM cells injected into Ly 5.2 congenic hosts were used as controls (n 5 10). Recipient mice were
considered Ly 5.1-reconstituted if greater than background (0.1%) levels of Ly 5.1 myeloid and lymphoid cells, as determined
by fluorescence-activated cell sorting, were present in the peripheral blood for at least 12 weeks post-transplantation. MBT 5
Myeloid, B cell, and T cell. Yates-corrected x2 analysis did not reveal any statistical difference (P . 0.05) between BrdUrd
KTSL2 and control KTSL2. CLDCR values are donor MBT-reconstituted miceytotal no. of host mice.
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BrdUrd-positive (Fig. 2 A). In mice fed for 180 days with
BrdUrd, .99% of KTSL2 incorporated BrdUrd (Fig. 2A).
Thus, all LT-HSC divide regularly during steady-state hema-
topoiesis, and no subset remains dormant.
When the percentage of BrdUrd negative cells was plotted
against time in a log-linear fashion as in Fig. 2B, the data
closely approximated a straight line. This indicates that a
constant fraction of HSC, about 7.8% per day, entered the cell
cycle in an apparently random fashion (24). From the log-
linear plot we interpolated the 50% BrdUrd incorporation
point for all MPP and for LT-HSC: 2.8 and 7.4 days, respec-
tively. The potential doubling time of asynchronously dividing
cells is the amount of time necessary for 77% of cells to
incorporate BrdUrd (25). Thus, the potential doubling time of
all MPP and LT-HSC was 7.7 days and 17.8 days, respectively.
Finally, the 99% BrdUrd-incorporation point was extrapolated
from the log-linear plot as about 57 days for LT-HSC.
LT-HSC Express Cyclin D2 mRNA. The small percentage of
LT-HSC with .2n DNA, and their relative resistance to
cytoreductive agents such as 59-f luorourocil led to the hypoth-
esis that LT-HSC are mostly quiescent (26–29). However, their
surprisingly rapid uptake of BrdUrd demonstrates that LT-
HSC are more active that previously thought. D cyclins are a
family of highly homologous proteins with three known mem-
bers expressed in a tissue-specific manner (30). D cyclins
integrate extracellular proliferative signals with the cell cycle
machinery to control progress through G1 (31). D cyclin
mRNA expression begins in early G1, and both protein and
mRNA are rapidly turned over (32, 33). Thus, only actively
proliferating cells should express significant amounts of cyclin
D mRNA. We performed RT-PCR on double-sorted KTSL2
LT-HSC to determine whether a significant fraction of these
cells express cyclin D. RT-PCR revealed that LT-HSC express
cyclin D2 (Fig. 3) and D3 but not D1 (data not shown). Cyclin
D2-positive results were obtained for 22 of 26 RT-PCR
reactions (85%) with 5 LT-HSC (Fig. 3A), and 27 of 63
RT-PCR reactions (43%) with one cell were positive (Fig. 3B).
Thus, nearly half of LT-HSC express cyclin D2 mRNA,
suggestive of cell cycle activity in a significant fraction of
LT-HSC.
Determination of the Proportion of LT-HSC in Cycle Using
PY and Hoechst. During cell cycle progression, there is a
constant increase of cellular RNA, mainly because of the
increased production of ribosomal RNA (34, 35). Quiescent
cells have, on average, 10–20% the RNA as their cycling
counterparts (36). Simultaneous staining of viable cells with
the RNA-specific f lourochrome PY and the DNA-specific
f luorochrome Hoechst has been widely used to determine the
cell cycle status of many different cell types (20). By using this
technique, the fraction of KTSL2 in G1ySyG2yM vs. G0 can be
determined, revealing the fraction of actively proliferating
cells (growth fraction) in vivo. As seen in Fig. 4, a significant
fraction of KTSL2 cells with a 2n amount of DNA had the
same or greater PY staining levels as SyG2yM KTSL2. Ac-
cording to this analysis, these PY-high, 2n cells were in G1
phase of the cell cycle. In three separate experiments analyzing
2,000–5,000 cells, 23.5 6 3.4% of KTSL2 contained RNA
levels consistent with G1ySyG2yM cells. Thus, during steady-
FIG. 1. Double-sorting is necessary to obtain pure KTSL2/lo and KTSL2 cells. (Upper) c-kit (y-axis) and lineage (x-axis) density plots with
outliers. Boxes indicate sort gates for KTSL2/lo (inner and outer boxes) and KTSL2 (inner boxes only). (Lower) Sca-1 (y-axis) and Thy 1.1 (x-axis)
density plots with outliers. Boxes indicate sort gates for KTSL2/lo and KTSL2 cells. As seen in the second and third columns, significant numbers
of cells outside the sort gates are present in a reanalysis of a single sorted sample. After the samples are double-sorted, the great majority of cells
($95%) are within the sort gates that define KTSL2/lo (fourth column) and KTSL2 (fifth column) HSC.
FIG. 2. In vivo BrdUrd incorporation kinetics of KTSL2/lo and KTSL2 cells. (A) BrdUrd incorporation rate of KTSL2/lo cells (h) and KTSL2
cells (F). Each data point represents mean percentages of BrdUrd positive HSC from at least two separate experiments with a combined analysis
of at least 500 cells. Some error bars are smaller than their associated symbol. (B) BrdUrd incorporation means plotted in semilogarithmic fashion
as the proportion of BrdUrd-negative KTSL2/lo cells (h) and KTSL2 cells (F) against time in days. The lines were generated by using least squares
fit linear regression.
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state hematopoiesis, about one-fourth of LT-HSC were in the
cell cycle, whereas the remaining were quiescent G0 cells.
Throughout the age cohort used in this study, LT-HSC
maintain constant numbers, balancing cell production with cell
loss (3, 37). Because LT-HSC are a population of asynchro-
nously dividing cells undergoing steady-state kinetics, BrdUrd
incorporation rates can be related to the fraction of prolifer-
ating cells and average cell cycle time by the following equa-
tion: RB 5 GFyTC, where RB is the BrdUrd incorporation rate
(0.078yday in this study), GF is the fraction of proliferating
cells or growth fraction (0.235 in this study), and TC is the
apparent cell cycle time (equation adapted from ref. 24). The
TC in this equation averages the cell cycle time of cells in cycle
and cells not yet in cycle. Thus, the actual cell cycling time of
a LT-HSC once in cycle is actually shorter (24). By using the
equation above, the estimated apparent in vivo cell cycle time
of KTSL2 LT-HSC under steady-state conditions was 3.0 days.
DISCUSSION.
We analyzed the in vivo proliferation and cell cycle kinetics of
C57BLyKa-Thy 1.1 mouse KTSL2ylo and KTSL2 HSC. Over
90% of LT-HSC entered the cell cycle at least once every 30
days, and by 6 months .99% of LT-HSC divided. The subsets
of cells analyzed in this experiment included all HSC in this
mouse strain (18). Thus, there was no subset of LT-HSC that
remained dormant for long periods of time. As determined by
the slope of the log-linear plot of BrdUrd incorporation versus
time (Fig. 2B), the probability of a LT-HSC entering the cell
cycle was about 0.08 each day. The apparent duration of the
LT-HSC cell cycle was 3.0 days. RT-PCR analysis of LT-HSC
revealed that .40% expressed significant amounts of G1 cyclin
D2. Consistent with this, simultaneous PY and Hoechst stain-
ing of LT-HSC revealed that about one-fourth of LT-HSC
were in G1ySyG2yM during steady -state hematopoiesis. As-
suming that 8% of LT-HSC go into cycle each day and that
24% of HSC are in G1ySyG2yM phases of the cell cycle, we
calculated an apparent cell cycle time of 3.0 days. Although this
number is helpful in considering the potential doubling time of
the population, it represents an average across an asynchro-
nous population of cycling and quiescent cells. Thus, the actual
cell cycle time of the dividing cells may be different. It should
also be noted that we used a conservative gate to determine the
percentage of LT-HSC in G1 phase by PY staining. It is
possible that some early G1 cells were excluded by this gate.
Our own experiments suggest that '40% of LT-HSC express
the G1 cyclin D2. If 40% of LT-HSC were in G1ySyG2yM
phases of the cell cycle, then the apparent cell cycle time would
be closer to 6 days.
The results of this study are consistent with those of Pietrzyk
et al. (14) and Bradford et al. (15), although we observed
somewhat faster incorporation of BrdUrd in the LT-HSC
fraction than was observed by Bradford et al. This could be
caused by the differences in mouse strains used, because the
cell cycle dynamics of HSC are likely to be mouse strain-
specific (38, 39). Also, Bradford et al. used the RhloHolo
method to isolate HSC, whereas we used KTSL as described
(3). Although both populations are highly enriched for long-
term reconstituting cells, they may not overlap completely in
terms of their composition.
In addition to varying between strains, cell cycle parameters
vary during ontogeny. For example, the number of fetal liver
HSC doubles daily, and around one-fourth of LT-HSC in the
fetal liver are in SyG2yM phases of the cell cycle at any one
time (40). HSC in old (.20 months) but otherwise normal
C57BL mice exhibit increased proportions of HSC in cycle
(37). Thus, whereas HSC in normal steady-state bone marrow
cycle slowly, at other times during ontogeny increased propor-
tions of HSC can be recruited into cycle, and cell cycle times
can be much faster.
Because the size of the LT-HSC pool remains constant and
does not increase under steady-state conditions in mice of this
age (37), dividing LT-HSC must give rise to equal numbers of
LT-HSC and other cell types, presumably short-term HSC.
This could be accomplished by each LT-HSC undergoing an
asymmetric division or by undergoing symmetric divisions in
which half yield two LT-HSC and half yield two cells that
differentiate or die.
The in vivo proliferation kinetics of HSC does not support
the clonal-succession model. Our data demonstrate that LT-
HSC enter the cell cycle in an asynchronous manner, that
FIG. 3. Cyclin D2 expression in five (A) and one (B) KTSL2 cells
as determined by using nested RT-PCR. No RT indicates lanes with
RT-PCR reactions performed on KTSL2 without the initial addition
of reverse transcriptase to the RT reactions as a control.
FIG. 4. Growth Fraction of KTSL2 LT-HSC. FACS analysis of
double-sorted KTSL2 cells stained with PY (y axis) and Hoechst 33342
(x axis). The growth fraction of a population of cells is the fraction of
actively dividing cells (G1/S/G2/M). On average, 23.5 6 3.4% of
KTSL2 LT-HSC were in G1/S/G2/M at any one time.
FIG. 5. Model of LT-HSC cell cycle regulation. LT-HSC are
asynchronously dividing with a constant fraction of cells in the cell
cycle and a constant fraction in G0. LT-HSC are continuously moving
into and out of the cell cycle at rates indicated next to the arrows (p
denotes probability of labeled event occurring) as determined from the
BrdUrd incorporation kinetics of KTSL2 cells. Tc 5 apparent cell
cycle time.
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proliferation was not dominated by a few clones, and that on
average 99% of LT-HSC divide every 57 days. Harrison et al.
(13, 41) showed that in normal chimeric mice, many HSC
contribute simultaneously to hematopoiesis. Recent experi-
ments in our laboratory show that if several hundred retrovi-
rus-infected LT-HSC were used to rescue lethally irradiated
mice, then at least seven clones contributed to mature blood
cells by Southern analysis at 25 weeks post-transplantation (C.
Klug and I.L.W., unpublished observations). These results
were consistent with the idea that if larger numbers of retro-
virus-marked HSC are transplanted, larger numbers of clones
durably contribute to hematopoiesis.
Model of LT-HSC Cell Cycle Regulation. In light of our data
on LT-HSC cell cycle kinetics, a more complete model of how
these cells proliferate and contribute to blood cell production
under normal hematopoietic situations can be considered (Fig.
5). At any one time, a fraction of LT-HSC would be in the cell
cycle (at least 23.5 6 3.4% in this study), and the remaining
LT-HSC would be in G0. Because most LT-HSC are quiescent,
the only explanation for the rapid incorporation of BrdUrd
into LT-HSC is that these cells are continuously moving into
and out of the cell cycle, as indicated by arrows in Fig. 5. The
fraction of cells in each compartment remains relatively con-
stant unless hematopoietic demands are altered significantly.
For example, we have observed that most or all LT-HSC are
driven to self-renew with a cell cycle time of ,12 hours in mice
that are stressed by administration of cyclophosphamide and
granulocyte colony stimulating factor (42). All LT-HSC in
cytoxanyG-CSF-treated mice label with BrdUrd after only 4
days of continuous feeding (D. Wright and I.L.W., unpublished
observation). Also, blocking KTSL2ylo in the S phase by the
administration of hydroxyurea to mice leads to a rapid increase
in the percentage of these cells in-cycle (43). Thus, although
the cell cycle time of HSC was relatively slow under steady-
state conditions, it is highly responsive to changes in the
hematopoietic environment. The proposed model provides a
highly adaptable system for hematopoiesis in which blood cell
production could be controlled in part by regulating the
fraction of LT-HSC in cycle andyor their average cell cycle
time.
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